ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SVRA vs ORIC // RSI-14 & 200D SMA MOMENTUM

Savara Inc. (NASDAQ) VS. Oric Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SVRA 4 — ORIC 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: SVRA
rsi-technicals
49.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SVRA VS. ORIC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SVRA ORIC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -33.40% -1.60 ORIC /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.94% -11.99% +2.05 SVRA /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 SVRA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 49.2 34.3 +14.90 SVRA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $990.3M $957.8M $32.6M SVRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SVRA REV ORIC REV SVRA GROSS % ORIC GROSS % SVRA FCF ORIC FCF
FY 2025 $345.9M $400.4M — — -$101.1M -$111.7M
FY 2024 $288.9M $400.1M — — -$89.1M -$113.8M
FY 2023 $168.0M $310.2M — — -$51.1M -$85.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SVRA // BETA —
ORIC // BETA —